resiquimod has been researched along with Glioma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogdahn, U; Chirasani, SR; Gottfried, E; Grauer, OM; Gronwald, W; Hau, P; Hochrein, J; Kreutz, M; Leukel, P; Neumann, B; Oefner, PJ; Stadler, K | 1 |
1 other study(ies) available for resiquimod and Glioma
| Article | Year |
|---|---|
Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Marrow Cells; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Diclofenac; Disease Models, Animal; Female; Glioma; Imidazoles; Immune Tolerance; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-2 Receptor alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Lactic Acid; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Phosphorylation; T-Lymphocytes, Regulatory; Transcriptional Activation; Up-Regulation | 2013 |